Temozolomide News and Research

RSS

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

New microfluidic chip predicts personalized glioblastoma treatment responses

Even for the same brain tumor treated with the same anticancer drug, the effect can differ from patient to patient.

17 Aug 2026

Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation

Several cannabinoids reduced chemotherapy- and radiation-induced apoptosis in glioblastoma cell models, with effects linked to reduced apoptotic priming, increased pro-survival signaling, and G1 cell-cycle arrest. The findings raise concern that cannabinoid exposure could interfere with some cancer treatments, although the results are limited to laboratory models and require in vivo and clinical validation.

12 Aug 2026

Immune cell interaction timing impacts glioblastoma treatment response

A joint research team led by Professor Sungsu Park of Sungkyunkwan University and Professor Sun-Ha Paek of Seoul National University College of Medicine has demonstrated for the first time that the sequence in which immune cells interact with cancer cells can critically influence the therapeutic response in glioblastoma.

10 Aug 2026

Patient-derived tumor models strengthen precision oncology research

A research project funded by the National Institutes of Health (NIH), with collaborators around the country and the world, has generated one of the most extensive and diverse collections of patient-derived tumor models.

5 Aug 2026

Multimodal surgery improves outcomes for rare corpus callosum glioma

Brain tumor surgeries are particularly challenging due to the difficult trade-off neurosurgeons often face—remove more tumor and risk neurological injury, or preserve function and leave more tumor behind.

17 Jul 2026

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, suggests a study in preclinical models co-led by researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham.

12 Jul 2026

Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma

Scientists have identified a promising new strategy to tackle one of the biggest obstacles in treating glioblastoma, one of the most aggressive form of brain cancer: resistance to chemotherapy.

9 Jul 2026

Drug-filled nanofibers offer potential breakthrough treatment for brain cancer

Researchers with the University of Cincinnati and Johns Hopkins Medicine developed a potential treatment for brain cancer that uses nanofibers embedded with a combination of drugs that work in concert to target tumors.

28 May 2026

Vitamin B12 analog targets deadly brain cancer cells

A new research paper was published in Volume 13 of Oncoscience on April 2, 2026, titled "Selective blood–brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide."

21 May 2026

Hyperbaric oxygen therapy shows dual effects in glioblastoma treatment

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment is a key contributor to its therapy resistance.

23 Apr 2026

Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma

A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma, a type of brain cancer.

16 Mar 2026

Researchers identify key factor to help improve treatment for glioblastoma

A groundbreaking study from Brown University Health researchers has identified a crucial factor that may help improve treatment for glioblastoma, one of the most aggressive and common forms of adult brain cancer.

30 Jan 2026

New breakthrough could modernize treatment for glioblastoma

Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could modernize treatment for glioblastoma, a fast-growing and deadly form of brain cancer.

6 Jan 2026

Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children

Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial.

12 Dec 2025

Focused ultrasound combined with chemotherapy improves survival in glioblastoma patients

Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40 percent increase in overall survival in a landmark trial of 34 patients led by University of Maryland School of Medicine (UMSOM) researchers.

24 Nov 2025

RNA-based cocktail shows promise against glioblastoma

A patented RNA-based cocktail developed at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has emerged as a promising active agent against tumors of the central nervous system, such as glioblastoma.

20 Nov 2025

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite standard care involving surgery, radiation, and temozolomide chemotherapy.

30 Oct 2025

New approach protects the brain from radiation-induced cognitive decline

While tremendous relief comes from successfully battling cancer, survivors can also experience cognitive impairments caused by the disease and its treatment.

14 Oct 2025

Proton therapy dose escalation may improve outcomes for glioblastoma patients

Previously, results from the photon cohort of the NRG-BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not demonstrate improvement in overall survival (OS) for patients with newly diagnosed glioblastoma (GBM).

30 Sep 2025